Guangzhou Innogen Pharmaceutical Group Co Ltd
Company Profile
Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
96
Stocks News & Analysis
stocks
Apple earnings: Strong performance overpowers headwinds, and we raise our FVE
stocks
Coles is winning the supermarket wars but is Woollies the better long-term opportunity?
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,182.50 | 24.00 | 0.26% |
| CAC 40 | 8,136.14 | 15.07 | 0.19% |
| DAX 40 | 24,140.00 | 181.70 | 0.76% |
| Dow JONES (US) | 47,562.87 | 40.75 | 0.09% |
| FTSE 100 | 9,732.65 | 15.40 | 0.16% |
| HKSE | 26,158.36 | 251.71 | 0.97% |
| NASDAQ | 23,724.96 | 143.81 | 0.61% |
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% |
| NZX 50 Index | 13,556.30 | 7.98 | 0.06% |
| S&P 500 | 6,840.20 | 17.86 | 0.26% |
| S&P/ASX 200 | 8,894.80 | 36.20 | 0.41% |
| SSE Composite Index | 3,976.52 | 21.73 | 0.55% |